Non Cash Royalty Revenue Related To Sale Of Future Royalties99%
License Collaboration And Other Revenue1%
By geography
Non-US100%
The read
Nektar Therapeutics booked $55.2M in FY2025 revenue, contracting 44% year over year — slower than 80% of Healthcare companies we track, at a -297.1% net margin.
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.